Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study

MLA

Si-Yang Liu, et al. “Neoadjuvant Nivolumab with or without Platinum-Doublet Chemotherapy Based on PD-L1 Expression in Resectable NSCLC (CTONG1804): A Multicenter Open-Label Phase II Study.” Signal Transduction and Targeted Therapy, vol. 8, no. 1, Dec. 2023, pp. 1–10. EBSCOhost, https://doi.org/10.1038/s41392-023-01700-4.

APA

Si-Yang Liu, Song Dong, Xue-Ning Yang, Ri-Qiang Liao, Ben-Yuan Jiang, Qun Wang, Xiao-Song Ben, Gui-Bin Qiao, Jun-Tao Lin, Hong-Hong Yan, Li-Xu Yan, Qiang Nie, Hai-Yan Tu, Bin-Chao Wang, Jin-Ji Yang, Qing Zhou, Hong-Rui Li, Ke Liu, Wendy Wu, … Yi-Long Wu. (2023). Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study. Signal Transduction and Targeted Therapy, 8(1), 1–10. https://doi.org/10.1038/s41392-023-01700-4

Chicago

Si-Yang Liu, Song Dong, Xue-Ning Yang, Ri-Qiang Liao, Ben-Yuan Jiang, Qun Wang, Xiao-Song Ben, et al. 2023. “Neoadjuvant Nivolumab with or without Platinum-Doublet Chemotherapy Based on PD-L1 Expression in Resectable NSCLC (CTONG1804): A Multicenter Open-Label Phase II Study.” Signal Transduction and Targeted Therapy 8 (1): 1–10. doi:10.1038/s41392-023-01700-4.